6533b7d8fe1ef96bd126ace7

RESEARCH PRODUCT

Harnessing HLA‐E‐restricted CD8 T lymphocytes for adoptive cell therapy of patients with severe COVID‐19

Lucy C. SullivanFrancesco DieliAndrew G. BrooksNadia Caccamo

subject

medicine.medical_specialtyLymphocyte TransfusionHematologymedicine.drug_classbusiness.industryvirusesmedicine.medical_treatmentHematologyImmunotherapyLung injuryMonoclonal antibodyVirus03 medical and health sciences0302 clinical medicineHLA-E030220 oncology & carcinogenesisInternal medicineImmunologymedicinebusinessCD8030215 immunology

description

SARS-CoV-2 is spreading worldwide, and is a pandemic virus that has infected almost 5 million individuals and causing 300.000 deaths, as of mid-May 2020. Because SARS-CoV-2 is a new virus in humans there are currently no vaccines, monoclonal antibodies (mAbs) or even effective drugs available. Human convalescent plasma transfusion is an option for either prophylactic or therapeutic treatment of COVID-19 patients, but its administration to patients who are affected by severe pulmonary disease is associated with increased risk of transfusion-related acute lung injury (TRALI).

yearjournalcountryeditionlanguage
2020-06-19British Journal of Haematology
https://doi.org/10.1111/bjh.16895